A Two-Part Controlled Clinical Study to Evaluate Safety, Tolerability, Response, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of GM-1020 in Patients With Major Depressive Disorder
Latest Information Update: 06 May 2024
At a glance
- Drugs GM 1020 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Gilgamesh Pharmaceuticals
Most Recent Events
- 01 May 2024 According to a Gilgamesh Pharmaceuticals media release, initial results of the Phase 2a trial anticipated to be available in the 2nd half of 2024.
- 01 May 2024 According to a Gilgamesh Pharmaceuticals media release, patient dosing has been initiated with GM-1020.
- 26 Sep 2023 New trial record